

Current share price
Background
Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSUL®) to treat Osteoarthritis (OA) – a market with over 31m sufferers in the USA alone.
More details about our programme can be found here.
Current shareholders click here to access and update your personal details.